Management of Node-Positive and Oligometastatic Prostate Cancer

被引：8
|
作者：
Broughman, James R. [1 ,2 ]
Chen, Ronald C. [1 ,2 ,3 ]
机构：
[1] Univ North Carolina Chapel Hill, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA
[3] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
来源：
SEMINARS IN RADIATION ONCOLOGY | 2017年 / 27卷 / 01期
关键词：
STEREOTACTIC BODY RADIOTHERAPY; METASTATIC COLORECTAL-CANCER; DELAYED ENDOCRINE TREATMENT; TERM-FOLLOW-UP; RADICAL PROSTATECTOMY; ANDROGEN-DEPRIVATION; RADIATION-THERAPY; LOCAL TREATMENT; HEPATIC RESECTION; PRIMARY TUMOR;
D O I：
10.1016/j.semradonc.2016.08.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Historically, stage IV prostate cancer was considered incurable. Although node-positive and oligometastatic prostate cancers are both classified as stage IV, these likely represent distinct clinical groups, and some patients may be curable with aggressive multimodality treatments. There is a lack of randomized evidence, but retrospective studies suggest that radical prostatectomy or radiotherapy may improve survival in these patients. This is an area of great current research interest and prospective randomized trials are needed to help define the optimal treatments for these patients. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：79 / 86
页数：8
相关论文
共 50 条
  • [11] Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer
    Mallick, I
    Das, A.
    Arunsingh, M.
    CLINICAL ONCOLOGY, 2019, 31 (04) : 260 - 264
  • [12] Treatment options in lymph node-positive prostate cancer
    Swanson, GP
    Thompson, IM
    Basler, J
    CANCER, 2006, 106 (12) : 2531 - 2539
  • [13] Is node-positive prostate cancer always a systemic disease?
    Briganti, Alberto
    Chun, Felix K.
    Karakiewicz, Pierre I.
    Rigatti, Patrizio
    Montorsi, Francesco
    EUROPEAN UROLOGY, 2008, 54 (02) : 243 - 246
  • [14] Extranodal extension in lymph node-positive prostate cancer
    Cheng, L
    Pisansky, TM
    Ramnani, DM
    Leibovich, BC
    Cheville, JC
    Slezak, E
    Bergstralh, EJ
    Zincke, H
    Bostwick, DG
    MODERN PATHOLOGY, 2000, 13 (02) : 113 - 118
  • [15] Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer
    Muralidhar, Vinayak
    Mahal, Brandon A.
    Rose, Brent S.
    Chen, Yu-Wei
    Nezolosky, Michelle D.
    Efstathiou, Jason A.
    Beard, Clair J.
    Martin, Neil E.
    Orio, Peter F., III
    Quoc-Dien Trinh
    Choueiri, Toni K.
    Sweeney, Christopher J.
    Nguyen, Paul L.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 563 - +
  • [16] Whole pelvis radiotherapy for pathological node-positive prostate cancer
    Poelaert, Filip
    Fonteyne, Valerie
    Ost, Piet
    De Troyer, Bart
    Decaestecker, Karel
    De Meerleer, Gert
    De Visschere, Pieter
    Claeys, Tom
    Dhondt, Bert
    Lumen, Nicolaas
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (06) : 444 - 451
  • [17] Node-Positive Prostate Cancer: A Call for Level 1 Evidence
    Gandaglia, Giorgio
    Karnes, R. Jeffrey
    Cozzarini, Cesare
    Montorsi, Francesco
    Briganti, Alberto
    ONCOLOGY-NEW YORK, 2015, 29 (02): : 118 - +
  • [18] Toxicity and outcome of pelvic IMRT for node-positive prostate cancer
    Mueller, A. -C.
    Luetjens, J.
    Alber, M.
    Eckert, F.
    Bamberg, M.
    Schilling, D.
    Belka, C.
    Ganswindt, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (11) : 982 - 989
  • [19] Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
    Wong, Yu-Ning
    Freedland, Stephen
    Egleston, Brian
    Hudes, Gary
    Schwartz, J. Sanford
    Armstrong, Katrina
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) : 100 - 105
  • [20] Node-positive prostate cancer. Value of radical prostatectomy
    Heidenreich, A.
    Schrader, A. J.
    UROLOGE, 2010, 49 (10): : 1266 - 1273
12345